About the Working Group
The UAB Lung Cancer Working Group is a multidisciplinary team consisting of thoracic-lung surgeons, radiation oncologists, medical oncologists, pathologists, pharmacologists, biostatisticians and research oncology nurses. One of the main goals of the working group is to develop novel therapeutic strategies for the treatment of lung cancer. Different clinical trials are being conducted by this group, including phase I, II and III trials. This multidisciplinary team will promptly evaluate new patients for therapy.
To find more information concerning this working group and novel lung cancer therapies contact Dr. Francisco Robert at the UAB Comprehensive Cancer Center (205-934-5077). Currently available Lung Cancer Clinical Trials are listed below. Please click on the title of each clinical trail for further information.
UAB 9909A Phase Ib, IIa Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination with Gemcitabine/Carboplatin in Patients with Chemotherapy Naive Stage IV Non-Small Cell Lung Cancer.
UAB 0162Neoadjuvant Chemoradiotherapy (Gemcitabine/Cisplatin and Taxotere) with or without Co-Administration of ZD 1839 (IRESSA) for Stage IIIA (N2) and Selective Stage IIIB Non-Small Cell Lung Cancer: Phase I-II Study.
UAB 0151A Phase II study of epothilone analog BMS-247550 in patients with non-small cell lung cancer who have failed first-line platinum based chemotherapy.
UAB 0161A Phase I/IIA Study of RPR109881A Administered in Combination with Carboplatin or Cisplatin as a First Line Chemotherapy in Untreated Patients with Non-Irradiable Stage IIIB or Stage IV Non-Small Cell Lung Cancer.
UAB 0255Phase I Open Label Study of the Combination of Gleevec (STI571) with Cisplatin and Etopiside for Previously Untreated Extensive Stage Small Cell Lung Cancer.
UAB 0251An Open Lavel Randomized Phase II/III Study Comparing Two Combination Modalities of IV HMR1275 (Flavopiridol) and IV Docetaxel (Taxotere) with IV Docetaxel (Taxotere) Alone in Patient with Non-Small Cell Lung (NSCLC) Previously Treated with Platinum-Based Chemotherapy.
UAB 0261Randomized Study of Doxetaxel Versus Docetaxel plus Genasense (BCL-2 Antisense Oligonucleotide) in Patients with Previously Treated Non-Small Cell Lung Cancer.
UAB 0149A Two Part, Multiple Dose Clinical Trial of the Safety and Efficacy of ABX-FBF in Combination with Paclicaxel and Corboplatin in Patients with Advanced Non-Small Cell Lung Cancer.